Skyflow Radically Simplifies Data Residency
26.5.2023 18:00:00 EEST | Business Wire | Press release
Today Skyflow, the data privacy vault company, announced new data residency capabilities including Asia-Pacific instances in Japan, Indonesia, India, and Bahrain, and an expansion of its footprint in EMEA and North America.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230526005072/en/
(Graphic: Business Wire)
With Skyflow, companies that store sensitive customer data can meet regulatory requirements for localized storage, provable and auditable data protection, and governance – simply by leveraging Skyflow’s global vault infrastructure. This enables global expansion to reach new customers in new markets, while minimizing complexity and cost. For example, SaaS ISVs can scale and sell their product in both EMEA and APAC without adding instances.
Replicating Instances is Expensive and Slow
Today, companies that want to expand internationally face a technically complex and expensive proposition: replicate all of your cloud infrastructure, databases, and data warehouses by adding instances in each region before onboarding new customers in that region.
As more countries implement data protection laws, some businesses that were previously compliant now face the need to re-architect their customer data platform (CDP) and cloud infrastructure.
With Skyflow, companies have a better option: add a data privacy vault in each region with data localization requirements, and store sensitive customer data in that local vault. Skyflow’s unique polymorphic encryption and tokenization capabilities let you do this without losing the ability to run workflows, analytics, or even machine learning while maintaining compliance.
Launch in New Regions in Weeks
One Skyflow customer, a Fortune 500 computer hardware company, was able to launch a new product in 30 countries across six regions in just three weeks without replicating their CDP or cloud infrastructure. They provisioned Skyflow vaults in each region, and stored their customer PII locally, all using Skyflow’s simple, yet powerful API.
“Our customers love that they can run their businesses globally without worrying about expensive replication and duplication. By isolating the PII and storing it locally, they meet localization requirements and also enhance security and governance controls,” said Anshu Sharma, co-founder and CEO of Skyflow. “We run a global network of cloud infrastructure so you don’t have to.”
“Skyflow enabled us to set up vaults in different regions quickly – such as Bahrain and the UAE – without having to spend money and resources replicating our infrastructure. Implementation was easy, so we were able to quickly start supporting customers across EMEA while ensuring privacy and compliance," said Michael Tomlins, co-founder and CEO of Apaya.
Read about Skyflow’s data residency solution here.
About Skyflow
Skyflow is a data privacy vault company built to radically simplify how companies isolate, protect and govern their customers’ most sensitive data. With its global network of data privacy vaults, Skyflow helps companies meet complex data localization requirements. Skyflow customers span verticals like fintech, retail, travel, and healthcare. Skyflow is headquartered in Palo Alto, California and was founded in 2019. For more information, visit www.skyflow.com or follow on Twitter and LinkedIn.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230526005072/en/
Contact information
Ali Rae Hunt
alirae.hunt@skyflow.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FPT Named an OpenAI Select Partner6.8.2026 03:00:00 EEST | Press release
Global IT corporation FPT today announced that it has been named an OpenAI Select Partner within the OpenAI Partner Network. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260805503787/en/ FPT Named an OpenAI Select Partner The OpenAI Partner Network is a global program for partners to build, sell, and deliver AI solutions with OpenAI. It brings together partners with deep industry expertise, delivery capabilities, and customer relationships while equipping them with resources, enablement, and support to help enterprises adopt OpenAI frontier models and products and turn them into measurable impact. As an OpenAI Select Partner, FPT will continue working with OpenAI to help organizations build, deploy, and scale AI solutions responsibly and effectively. This work will help organizations get more useful work from every token and stronger performance per dollar with GPT‑5.6, while using ChatGPT Work to turn ambitious goals into
U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 16.8.2026 01:10:00 EEST | Press release
Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) approved ORZEYFUL™ (oveporexton), an oral orexin receptor 2 (OX2R) agonist, for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults.* The persistent 24-hour nature of NT1 is driven by orexin deficiency and can severely impact people’s lives. As a first-in-class orexin treatment, ORZEYFUL is the only medicine indicated in the U.S. to treat the disease holistically rather than individual symptoms. “The FDA approval of ORZEYFUL marks a new chapter for the narcolepsy type 1 community, as we introduce an entirely new class of medicine that will potentially redefine how this disease is managed and howpeople feel on treatment,” said Julie Kim, president and chief executive officer of Takeda. “We are proud to have discovered and developed this orexin treatment innovation and will bring it to adults living with NT1 as quickly as possible.” NT1 is a rare, chronic neurological disease d
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.8.2026 23:30:00 EEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to fourteen newly hired non-executive employees. The equity awards were granted on August 3, 2026 and consisted of options to purchase an aggregate of 139,355 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 66,300 shares. The options have an exercise price per share equal to $11.25, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restricted
Clinilabs Announces Medical Leadership Appointments5.8.2026 17:05:00 EEST | Press release
Clinilabs (“Clinilabs LLC”), a global, full-service contract research organization (CRO) specializing in central nervous system (CNS) drug and device development, today announced the appointments of Bob Dagher, M.D., as Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., as Principal Investigator of the Company’s Eatontown, New Jersey Clinical Research Unit (CRU). Dr. Dagher will provide strategic and medical leadership across the organization, while Dr. Siddiqui will lead the execution of research projects at the Company’s CRU. Together, they will support the design, development, and execution of clinical programs for pharmaceutical, biotechnology, and medical device sponsors advancing innovative therapies for psychiatric, neurological, substance use, and rare CNS disorders. “Clinilabs has earned the trust of sponsors by combining deep scientific expertise, medical leadership, and operational excellence with a track record of execution from first-in-human studies through regulatory
Interactive Brokers Adds Brazilian Futures through Brazil’s B3 Exchange5.8.2026 17:00:00 EEST | Press release
Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced that eligible clients outside of Brazil can now trade Brazilian futures in addition to equities through the B3 exchange. Interactive Brokers was the first broker to provide international investors with streamlined, low-cost access to B3. Offering Brazilian futures and equities alongside products across more than 170 markets worldwide underscores IBKR’s commitment to broadening global market access and giving clients efficient, cost-effective ways to diversify through a single, unified platform. Access to B3 provides exposure to one of Latin America’s most active and liquid markets, providing long-term growth potential across multiple sectors and another way for investors to pursue emerging market opportunities. "Global investors deserve seamless, low-cost access to the world's most compelling markets, including emerging economies shaping tomorrow's financial landscape," said Milan Galik, Chief Executive Off
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom